Carregant...
Systemic Treatment Options in Hepatocellular Carcinoma
BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) typically have poor survival outcomes. Until recently, sorafenib was the only systemic therapy option available and no agents were approved after sorafenib failure. However, rapid changes are beginning to emerge in the treatment lands...
Guardat en:
| Publicat a: | Liver Cancer |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
S. Karger AG
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6883446/ https://ncbi.nlm.nih.gov/pubmed/31799201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000499765 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|